🇺🇸 FDA
Patent

US 9913843

Protein kinase C inhibitors and uses thereof

granted A61KA61K31/506A61K31/5377

Quick answer

US patent 9913843 (Protein kinase C inhibitors and uses thereof) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/506, A61K31/5377, A61K31/538, A61K31/5383